Darzalex Faspro® (daratumumab and hyaluronidase-fihj)  
(Subcutaneous)

I. Length of Authorization\textsuperscript{1,9,19,20}

Coverage will be provided for 6 months and may be renewed unless otherwise specified.

- Use for newly diagnosed multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone may not be renewed.
- Use for newly diagnosed disease in combination with bortezomib, lenalidomide and dexamethasone may be renewed for up to a maximum of 2 years of maintenance therapy.
- Use for newly diagnosed or relapsed disease in combination with cyclophosphamide, bortezomib and dexamethasone may be renewed for up to a maximum of 80 weeks (32 weeks of induction therapy and 48 weeks of maintenance therapy).
- Use for newly diagnosed systemic light chain amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone may be renewed for up to a maximum of 2 years.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Darzalex Faspro 1,800 mg/30,000 unit single-dose vial for injection: 1 vial per dose
  - Weekly Weeks 1 to 8, then every two weeks Weeks 9-24, then every four weeks Week 25 onwards

B. Max Units (per dose and over time) [HCPCS Unit]:

- Up to 180 billable units per dose
  - Weekly Weeks 1 to 8, then every two weeks Weeks 9-24, then every four weeks Week 25 onwards

III. Initial Approval Criteria\textsuperscript{1}

Coverage is provided in the following conditions:

- Patient is at least 18 years of age: AND
Universal Criteria ¹

- Therapy will not be used in combination with other anti-CD38 therapies (i.e., daratumumab, isatuximab, etc.): AND

Multiple Myeloma † Φ 1,2,6,14,16,17,19,20

- Used in the treatment of newly diagnosed disease in patients who are ineligible for autologous stem cell transplant (ASCT) in combination with ONE of the following regimens:
  - Lenalidomide and dexamethasone: OR
  - Bortezomib, melphalan and prednisone: OR
  - Cyclophosphamide, bortezomib, and dexamethasone: OR

- Used in the treatment of newly diagnosed disease in patients who are eligible for autologous stem cell transplant (ASCT) in combination with ONE of the following regimens:
  - Bortezomib, lenalidomide, and dexamethasone: OR
  - Bortezomib, thalidomide, and dexamethasone (VTd): OR
  - Cyclophosphamide, bortezomib, and dexamethasone: OR

- Used for disease relapse after 6 months following primary induction therapy with the same regimen in combination with ONE of the following regimens:
  - Lenalidomide and dexamethasone for non-transplant candidates: OR
  - Cyclophosphamide, bortezomib, and dexamethasone: OR

- Used as subsequent therapy in combination with dexamethasone and ONE of the following:
  - Lenalidomide: OR
  - Bortezomib: OR
  - Carfilzomib: OR
  - Cyclophosphamide and bortezomib: OR
  - Selinexor: OR

- Used in combination with pomalidomide and dexamethasone: AND
  - Used after at least ONE prior line of therapy including lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib, etc.): OR
  - Used after at least TWO prior therapies including an immunomodulatory agent (e.g., pomalidomide, etc.) and a proteasome inhibitor (bortezomib, carfilzomib, etc.): OR

- Used as single agent therapy: AND
  - Patient received at least three prior lines of therapy including a proteasome inhibitor (e.g., bortezomib, carfilzomib, etc.) and an immunomodulatory agent (e.g., lenalidomide, pomalidomide, etc.): OR
  - Patient is double-refractory to a proteasome inhibitor and an immunomodulatory agent
Systemic Light Chain Amyloidosis †‡ 1,2,15,18,21

- Patient must NOT have NYHA Class IIIB or Class IV, or Mayo Stage IIIB cardiac disease; AND
  - Used in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for newly diagnosed disease: OR
  - Used as single agent therapy for the treatment of relapsed/refractory disease

† FDA Approved Indication(s); ‡ Compendia recommended indication(s); ☐ Orphan Drug

IV. Renewal Criteria 1,2,6,9,19,20

Coverage can be renewed based upon the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III: AND
- Disease response with treatment as defined by stabilization of disease and decrease in size of tumor of tumor spread: AND
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: hypersensitivity and other administration reactions (e.g., systemic administration-related reactions, local injection-site reactions, etc.), neutropenia, thrombocytopenia, cardiac toxicity, etc.: AND

Multiple Myeloma

- Use for newly diagnosed disease in combination with bortezomib, thalidomide and dexamethasone after 24 weeks of induction/consolidation therapy may not be renewed.
- Use for newly diagnosed disease in combination with bortezomib, lenalidomide and dexamethasone may be renewed for up to a maximum of 2 years of maintenance therapy.
- Use for newly diagnosed or relapsed disease in combination with cyclophosphamide, bortezomib and dexamethasone may be renewed for up to a maximum of 80 weeks (32 weeks of induction therapy and 48 weeks of maintenance therapy).

Systemic Light Chain Amyloidosis (newly diagnosed disease)

- Use for newly diagnosed disease in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) may be renewed for a maximum of 2 years of therapy.

V. Dosage/Administration 1,6,8,15

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple Myeloma</td>
<td>Administer 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) as a 15 mL injection subcutaneously into the abdomen. Treatment as one of the following: Newly diagnosed disease in patients ineligible for ASCT in combination with bortezomib, melphalan and prednisone (D-VMP) (6-week cycle)</td>
</tr>
</tbody>
</table>
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management
### DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

**Prior Auth Criteria**

**Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
©2021, Magellan Rx Management**

<table>
<thead>
<tr>
<th>Systemic Light Chain Amyloidosis</th>
<th>Newly diagnosed disease in combination therapy with bortezomib, cyclophosphamide and dexamethasone (D-VCd) (4-week cycle):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Weekly  Weeks 1 to 9 (nine doses; cycles 1 to 3)</td>
</tr>
<tr>
<td></td>
<td>- Every three weeks Weeks 10 to 24 (five doses; cycles 4 to 8)</td>
</tr>
<tr>
<td></td>
<td>- Every four weeks  Week 25 onwards (cycle 9 and beyond)</td>
</tr>
<tr>
<td><strong>Treat until disease progression or unacceptable toxicity.</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Single agent therapy for relapsed/refractory disease (4-week cycle):</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Weekly  Weeks 1 to 8 (eight doses; cycles 1 and 2)</td>
</tr>
<tr>
<td></td>
<td>- Every two weeks  Weeks 9 to 24 (eight doses; cycles 3 to 6)</td>
</tr>
<tr>
<td></td>
<td>- Every four weeks  Week 25 onwards (cycle 7 and beyond)</td>
</tr>
<tr>
<td><strong>Treat until disease progression or unacceptable toxicity or a maximum of 2 years</strong></td>
<td></td>
</tr>
</tbody>
</table>

*Keep refrigerated. Darzalex Faspro should only be administered subcutaneously by a healthcare professional. Do NOT administer Darzalex Faspro intravenously.

Note: Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week after starting Darzalex and continue for 3 months following treatment. Refer to the PI for other pre- and post-medication therapies.

### VI. Billing Code/Availability Information

**HCPCS Code:**

- J9144 - Injection, daratumab, 10 mg and hyaluronidase-fihj; 1 billable unit=10 mg

**NDC:**

- Darzalex Faspro 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL single-dose vial: 57894-0503-xx

### VII. References


2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for daratumumab and hyaluronidase-fihj. National Comprehensive Cancer Network, 2021. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed July 2021.


4. Mateos MV, Nahi H, Legier W, et al. Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management


NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed July 2021.


Appendix 1 – Covered Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C90.00</td>
<td>Multiple myeloma not having achieved remission</td>
</tr>
<tr>
<td>C90.02</td>
<td>Multiple myeloma, in relapse</td>
</tr>
<tr>
<td>C90.10</td>
<td>Plasma cell leukemia not having achieved remission</td>
</tr>
<tr>
<td>C90.12</td>
<td>Plasma cell leukemia in relapse</td>
</tr>
<tr>
<td>C90.20</td>
<td>Extramedullary plasmacytoma not having achieved remission</td>
</tr>
<tr>
<td>C90.22</td>
<td>Extramedullary plasmacytoma in relapse</td>
</tr>
<tr>
<td>C90.30</td>
<td>Solitary plasmacytoma not having achieved remission</td>
</tr>
<tr>
<td>C90.32</td>
<td>Solitary plasmacytoma in relapse</td>
</tr>
<tr>
<td>E85.81</td>
<td>Light chain (AL) amyloidosis</td>
</tr>
<tr>
<td>E85.89</td>
<td>Other amyloidosis</td>
</tr>
<tr>
<td>E85.9</td>
<td>Amyloidosis, unspecified</td>
</tr>
<tr>
<td>Z85.79</td>
<td>Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues</td>
</tr>
</tbody>
</table>
Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: [http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx](http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx). Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>E (1)</td>
<td>CA, HI, NV, AS, GU, CNMI</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>5</td>
<td>KS, NE, IA, MO</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>6</td>
<td>MN, WI, IL</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>H (4 &amp; 7)</td>
<td>LA, AR, MS, TX, OK, CO, NM</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>8</td>
<td>MI, IN</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>N (9)</td>
<td>FL, PR, VI</td>
<td>First Coast Service Options, Inc.</td>
</tr>
<tr>
<td>J (10)</td>
<td>TN, GA, AL</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>M (11)</td>
<td>NC, SC, WV, VA (excluding below)</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>L (12)</td>
<td>DE, MD, PA, NJ, DC (includes Arlington &amp; Fairfax counties and the city of Alexandria in VA)</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>K (13 &amp; 14)</td>
<td>NY, CT, MA, RI, VT, ME, NH</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>15</td>
<td>KY, OH</td>
<td>CGS Administrators, LLC</td>
</tr>
</tbody>
</table>